정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1220 | Recruiting | Immunogenicity of COVID-19 Vaccine on Heterologous Schedule | Healthy | Biological: Heterologous prime-boost schedule with AZD1222 and MVC-COV1901 Biological: Homologous prime-boost schedule with two doses of AZD1222 |
Phase 2 | Chang Gung Memorial Hospital | OTHER | 110 | All | 20 Years ~ 70 Years | ChangGungMH, Taoyuan, Taiwan |
| 1219 | Active, not recruiting | Immunogenicity of VLA2101 Compared to VLA2001. | SARS-CoV-2 Virus Infection | Biological: VLA2001 Biological: VLA2101 |
Phase 3 | Valneva Austria GmbH | INDUSTRY | 900 | All | 12 Years | Southern Clinical Trials Waitemata, Auckland, Birkenhead, New Zealand Optimal Clinical Trials Ltd, Auckland, Grafton, New Zealand Lakeland Clinical Trials Waikato, Hamilton, Nawton, New Zealand Southern Clinical Trials Totara, Auckland, New Lynn, New Zealand P3 Research Wellington, Wellington, Newtown, New Zealand Lakeland Clinical Trials Culloden, Papamoa, Papamoa Beach, New Zealand Southern Clinical Trials Remuera, Auckland, Remuera, New Zealand Southern Clinical Trials Tasman, Nelson, Stoke, New Zealand Southern Clinical Trials Christchurch, Christchurch, New Zealand Lakeland Clinical Trials Rotorua, Rotorua, New Zealand |
| 1218 | Completed | Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine | Vaccine Adverse Reaction | Biological: QazCovid-in®-vaccine against COVID-19 Other: Placebo |
Phase 3 | Research Institute for Biological Safety Problems, City polyclinic No. 4 of the UZO of Almaty, Clinic of the International Institute of Postgraduate Education, City Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl Region | OTHER_GOV | 3000 | All | 18 Years | Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan |
| 1217 | Not yet recruiting | Immunoregulatory Therapy for 2019-nCoV | 2019 nCoV, PD-1 | Drug: PD-1 blocking antibody+standard treatment Drug: Thymosin+standard treatment Other: standard treatment |
Phase 2 | Southeast University, China | OTHER | 120 | All | 18 Years | |
| 1216 | Completed | Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction | Mood | Drug: Botulinum Neurotoxin Drug: Placebo |
Phase 1 | DeNova Research | OTHER | 45 | All | 10 Years ~ 75 Years | DeNova Research, Chicago, Illinois, United States |
| 1215 | Enrolling by invitation | Impact of Colchicine and Low-dose Naltrexone on COVID-19 | Covid19 | Drug: Colchicine 0.6 mg Drug: Naltrexone |
Phase 2 | HealthPartners Institute, Park Nicollet Foundation | OTHER | 164 | All | 18 Years | Park Nicollet Methodist Hospital, Saint Louis Park, Minnesota, United States Regions Hospital, Saint Paul, Minnesota, United States |
| 1214 | Not yet recruiting | Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 | Corona Virus Infection | Drug: Colchicine 0.5 MG Combination Product: CONTROL GROUP |
Phase 3 | Fundacion Universitaria de Ciencias de la Salud, Hospital de San Jose | OTHER | 128 | All | 18 Years | Fundacion Universitaria de Ciencias de La Salud, Bogota, Cundinamarca, Colombia |